Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients

Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients

Abstract Background Although advanced non-squamous non-small cell lung cancer (NSCLC) patients have significantly better survival outcomes after pemetrexed based treatment, a subset of patients still show intrinsic resistance and progress rapidly. Therefore we aimed to use a blood-based protein sign...

Full description

Bibliographic Details
Main Authors: Bo Jia, Zhi Dong, Di Wu, Jun Zhao, Meina Wu, Tongtong An, Yuyan Wang, Minglei Zhuo, Jianjie Li, Yang Wang, Jie Zhang, Xinghui Zhao, Sheng Li, Junfeng Li, Menglei Ma, Chen Chen, Xue Yang, Jia Zhong, Hanxiao Chen, Jingjing Wang, Yujia Chi, Xiaoyu Zhai, Song Cui, Rong Zhang, Qingwei Ma, Jian Fang, Ziping Wang
Format: Article
Language:English
Published: BMC 2020-12-01
Series:Cancer Cell International
Subjects:
Lung adenocarcinoma
Pemetrexed
Prognosis
Treatment
VeriStrat
Online Access:https://doi.org/10.1186/s12935-020-01662-5

Internet

https://doi.org/10.1186/s12935-020-01662-5

Similar Items